Search clinical trials for: Copegus

Total 205 results

Baqiyatallah Medical Sciences University
Shahid Beheshti University of Medical Sciences; Guilan University of Medical... and other collaborators

Completed

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Hemophilia | Hepatitis C

Iran, Islamic Republic of
University of Nebraska

Withdrawn

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

Chronic Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Hepatitis C, Chronic

United States, Puerto Rico
University Health Network, Toronto

Unknown

Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy

Hepatitis B | Hepatitis C

Canada
University Hospital, Bonn

Completed

Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

HIV Infections | Hepatitis C

Germany
Karolinska Institutet
The Swedish Research Council; Hoffmann-La Roche

Completed

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (DICO)

Chronic Hepatitis C | Human Immunodeficiency Virus

Sweden
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets

Healthy Volunteer

United States
Baqiyatallah Medical Sciences University
Guilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... and other collaborators

Completed

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Hepatitis C | Thalassemia

Iran, Islamic Republic of
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center

Terminated

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Hepatitis C, Chronic

Sweden, New Zealand, United States, France, Brazil
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Hepatitis C

Japan
Charles University, Czech Republic
IGA MZ, Czech Republic

Unknown

Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection

Nonalcoholic Steatohepatitis | Chronic HCV Infection

Czech Republic
Hoffmann-La Roche

Completed

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Healthy Volunteer

Mexico
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Hepatitis C

Austria
Rhode Island Hospital
National Institute of Mental Health (NIMH)

Enrolling by invitation

From Court to the Community (JJ-COPES)

Suicidal Thoughts and Behaviors

United States
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (SAEI_IFN_1)

HIV Infections | Hepatitis C, Chronic

Spain
Fundación Pública Andaluza para la gestión de la...

Completed

Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 (OPTIM)

Hepatitis C, Chronic

Spain
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

Japan
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic

United States, Canada, Australia, France, Germany, Austria, Italy
Debiopharm International SA

Completed

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Hepatitis C | Liver Disease

United States, France
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

Hepatitis D, Chronic

Italy
Hoffmann-La Roche

Completed

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Hepatitis C, Chronic

Slovenia
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Fasting Conditions

Healthy

United States
Gilead Sciences

Completed

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Hepatitis C

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
VA Connecticut Healthcare System
VA Office of Research and Development

Completed

Cooperative Pain Education and Self-management (COPES)

Chronic Low Back Pain

United States
Mashhad University of Medical Sciences

Completed

Effect of Camel Milk on Chronic Hepatitis C (HCV)

Chronic Hepatitis C

Iran, Islamic Republic of
Scynexis, Inc.

Completed

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Hepatitis C Infection

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Czechia, Slovakia
Grupo de Enfermedades Infecciosas de la Sociedad...

Unknown

Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C (Perseo)

Hepatitis C, Chronic | Personality Disorders in Prison

Spain
Hoffmann-La Roche

Completed

A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

Hepatitis C, Chronic

Greece
Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil
Santaris Pharma A/S

Unknown

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

Puerto Rico, United States
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Yale University
National Center for Complementary and Integrative Health (NCCIH)

Active, not recruiting

Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA) (COPES ExTRA)

Pain, Chronic

United States
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Conatus Pharmaceuticals Inc.

Completed

CTS-1027 in Interferon-Naive Hepatitis C Patients

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)

Hepatitis C, Chronic

United States, Puerto Rico
Bausch Health Americas, Inc.

Completed

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Chronic Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Hepatitis C, Chronic
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Bristol-Myers Squibb
Pharmasset

Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Chronic Hepatitis C

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Azienda Ospedaliera di Padova
University of Padova; Regione Veneto

Completed

Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.

Hepatitis C Virus | Chronic Liver Disease | Therapeutic Uses | Viral Hepatitis | Antiviral Agents

Italy
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Hoffmann-La Roche

Completed

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Hungary

3

Subscribe